ThymodepressinТимодепрессин
A synthetic two-amino-acid peptide (γ-D-Glu–D-Trp) studied as an immunosuppressant in psoriasis and other immune disorders.
What the studies found
Randomized study in people · 2018
Thymodepressin in perennial allergic rhinoconjunctivitis: KI-THYM-001 clinical-study report
- Primary nasal-symptom comparison
- p=0.6708; no significant between-group difference.Day 16
- Selected secondary symptoms and sleep
- Some comparisons favored treatment; these do not overturn the neutral primary outcome.
- Drug-related adverse events
- Reported in both groups; exact counts not extracted; comparison p=1.
The primary nasal-symptom comparison was nonsignificant (p=0.6708); selected secondary symptoms favored Thymodepressin.
Study notes · methods, sources and limitations
Participants or model 72 randomized, 36 per arm; one comparator withdrawal
Design Open randomized active-comparator allergy study; 72 randomized (36/36); one comparator withdrawal. Thymodepressin nasal spray versus standard care.
- Later follow-up
- Day 47±2, approximately 30 days after therapy.
Important limitations
- Open active-comparator design; nonsignificance does not establish noninferiority. Report dated 8 October 2018 precedes the listed 20 October study end; signed final version needs authentication. Allergy study, separate from rheumatoid-arthritis protocol ИБХ-ТД01.
- Superiority and noninferiority are not established. The report-date inconsistency and unsigned fields require a final-version check.
KI-THYM-001, Phase III report; permit 85, 26 February 2018 · Sponsor clinical-study report; not a journal publication
Comparison in people · 2014
Evaluation of the efficacy and safety of a Russian selective immune suppressor in treating patients with psoriasis
- PASI reduction greater than 75% by day 25
- 90% with Thymodepressin versus 41% with conventional care
The Russian text reports more than 75% PASI improvement by day 25 in 90% versus 41% in the moderate-disease comparison. Overall favorable outcomes were reported in 100% versus 82.9%.
Study notes · methods, sources and limitations
Participants or model 140 patients with moderate or severe psoriasis
Design 140-patient clinical comparison; the quoted PASI response appears within the moderate-psoriasis discussion.
Important limitations
- The paper gives these PASI percentages in its discussion of moderate psoriasis. The unclear denominator prevents estimating a response rate across all 140 patients. Blinding and allocation concealment are not established. Concurrent care and treatment selection limit causal attribution. The comparator reflects conventional care at publication, not contemporary targeted biologics.
- The subgroup denominator is not verified; these percentages must not be described as responses among all 140 participants. Blinding, allocation and concurrent treatment limit attribution.
Clinical Dermatology and Venereology. 2014;12(5):68–74 · Publication record
Animal research · 2021
Thymodepressin-Unforeseen Immunosuppressor
Experimental anti-fibrillarin autoantibody responses were lower in selected Thymodepressin groups, including comparisons begun after autoimmunity developed.
Study notes · methods, sources and limitations
Participants or model Small mouse autoimmunity experiments, approximately five to eight animals per group
Important limitations
- Small induced-animal model, not a human lupus trial. Comparisons against cyclosporine do not establish clinical superiority or equivalent human exposures. The article combines experimental results with historical clinical discussion; those evidence types must remain separate.
Molecules (Basel, Switzerland) · Publication record
About Thymodepressin
Names in this research collection
Timodepressin · γ-D-Glu-D-Trp · D-Glu-D-Trp
Research background
Synthetic γ-D-Glu-D-Trp immunosuppressive dipeptide. Russian reports cover psoriasis, autoimmune cytopenias and myositis; a rheumatoid arthritis trial registration has no verified results.
Autoimmune research: disease-specific findings, immune effects and open questions ↗
Conference sources and research collaborators ↗
- Compound class
- Synthetic immunosuppressive dipeptide
- Research collection
- Peptide bioregulation · editorial grouping
- Institutions in linked studies
- See individual study records
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
Small clinical comparisons and reports; RA protocol is not a result
Study methods
Source-specific designs and limitations below
Independent replication
Related reports are not automatically independent evidence
Source access
Original indexed abstracts and publisher texts; explicit access limits on each record
Safety evidence
Skin-eruption withdrawals reported in historical psoriasis literature; long-term comparative safety remains uncertain
Open a topic for the evidence assessment.
Patents and claimed inventions
These 3 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →
Findings by study
Experiment described in a patent · 2013
Thymodepressin: monosodium crystal polymorph — US8481588B2
The patent reports recovery of defined crystalline forms and conversion of a mixed preparation toward form F.
Selected conversion result · 38 mg recovered from a 50 mg portion, reported 78% yield; XRPD described as essentially form F · Analytical/manufacturing observation
Study notes and original source
Thymodepressin: monosodium crystal polymorph — US8481588B2
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Tim Fat Tam, Blaise N'Zemba, Regis Leung-Toung, Yingsheng Wang, Yanqing Zhao, Lily Yu · US8481588B2 · patent family 39687890
The patent reports recovery of defined crystalline forms and conversion of a mixed preparation toward form F.
Results and tables
Reported patent results
Reported findings
The patent reports recovery of defined crystalline forms and conversion of a mixed preparation toward form F.
Solid-form experiments comparing and interconverting monosodium Thymodepressin polymorphs.
Population or model Solid-form experiments comparing and interconverting monosodium Thymodepressin polymorphs.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Selected conversion result | 38 mg recovered from a 50 mg portion, reported 78% yield; XRPD described as essentially form F | Analytical/manufacturing observation |
| Different polymorph example | Form X recovery reported at 60% yield, melting interval 182.3–186.1°C | A different crystal form, not a clinical comparator |
Crystal-form recovery and diffraction identity do not establish better autoimmune outcomes, absorption or safety. Polymorphs must not be conflated.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Solid-form experiments comparing and interconverting monosodium Thymodepressin polymorphs.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- A distinct polymorph claim does not establish a different clinical mechanism or make every sodium formulation equivalent.
- Crystal-form recovery and diffraction identity do not establish better autoimmune outcomes, absorption or safety. Polymorphs must not be conflated.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-06.
Experiment described in a patent · 2012
Thymodepressin: crystalline salt development — US8138221B2
The potassium example reports high analytical purity and low measured water content.
Potassium-salt quality · 98.3% HPLC peak-area purity; water content 0.7% · Crystalline material characterized by diffraction; not a clinical efficacy endpoint
Study notes and original source
Thymodepressin: crystalline salt development — US8138221B2
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Tim Fat Tam, Blaise N'Zemba, Regis Leung-Toung, Yingsheng Wang, Yanqing Zhao, Lily Yu · US8138221B2 · patent family 39535926
The potassium example reports high analytical purity and low measured water content.
Results and tables
Reported patent results
Reported findings
The potassium example reports high analytical purity and low measured water content.
Physicochemical development of Thymodepressin salt forms; the granted US claims narrow to a particular potassium crystal.
Population or model Physicochemical development of Thymodepressin salt forms; the granted US claims narrow to a particular potassium crystal.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Potassium-salt quality | 98.3% HPLC peak-area purity; water content 0.7% | Crystalline material characterized by diffraction; not a clinical efficacy endpoint |
| Preparation recovery | Reported quantitative yield in the potassium example | Manufacturing recovery, not response or bioavailability |
Other salts in the description are not automatically within the granted claim. Analytical quality does not establish comparative clinical effectiveness or safety.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Physicochemical development of Thymodepressin salt forms; the granted US claims narrow to a particular potassium crystal.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- The broader abstract is not the granted claim set; a crystal-form patent does not establish superiority in clinical treatment.
- Other salts in the description are not automatically within the granted claim. Analytical quality does not establish comparative clinical effectiveness or safety.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-06.
Experiment described in a patent · 1998
Thymodepressin: D-amino-acid dipeptide claim — US5736519A
The patent reports context-dependent marrow recovery and improved survival in preclinical models.
Cytopenia experiment · Marrow karyocytes >2-fold, CFU-S-8 nearly 3-fold and CFU-S-12 >2-fold higher than cytostatic-only controls · 24 mice total; 12 received the peptide · Day 7 marrow examination
Study notes and original source
Thymodepressin: D-amino-acid dipeptide claim — US5736519A
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Vladislav I. Deigin, Andrei Marxovich Korotkov · US5736519A · patent family 20168146
The patent reports context-dependent marrow recovery and improved survival in preclinical models.
Results and tables
Reported patent results
Reported findings
The patent reports context-dependent marrow recovery and improved survival in preclinical models.
Thymodepressin-related D-amino-acid peptide mouse studies, including cytostatic-associated cytopenia and allogeneic marrow-transplant observations.
Population or model Thymodepressin-related D-amino-acid peptide mouse studies, including cytostatic-associated cytopenia and allogeneic marrow-transplant observations.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Cytopenia experiment | Marrow karyocytes >2-fold, CFU-S-8 nearly 3-fold and CFU-S-12 >2-fold higher than cytostatic-only controls | 24 mice total; 12 received the peptide · Day 7 marrow examination |
| Transplant-associated survival | 45-day survival described as almost doubled versus control | Absolute survivor counts and schedule-specific denominators not transcribed · 45 days |
Marrow recovery after injury does not mean general immune stimulation or prove autoimmune treatment benefit. These are animal observations with incomplete quantitative extraction.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Thymodepressin-related D-amino-acid peptide mouse studies, including cytostatic-associated cytopenia and allogeneic marrow-transplant observations.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- Linkage and stereochemistry distinguish this compound from Thymogen and Bestim; a patent does not demonstrate autoimmune efficacy.
- Marrow recovery after injury does not mean general immune stimulation or prove autoimmune treatment benefit. These are animal observations with incomplete quantitative extraction.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-06.
Randomized study in people · 2018
Thymodepressin in perennial allergic rhinoconjunctivitis: KI-THYM-001 clinical-study report
The primary nasal-symptom comparison was nonsignificant (p=0.6708); selected secondary symptoms favored Thymodepressin.
Study notes and original source
Thymodepressin in perennial allergic rhinoconjunctivitis: KI-THYM-001 clinical-study report
Thymodepressin nasal spray versus standard allergy care · Sponsor clinical-study report; not a journal publication
Format: Sponsor-hosted report PDF and companion HTML · Reviewed: Selected report text, pp. 24–25, 60–61 and 75–80. Annexes outside the review.
Triatop — sponsor report · KI-THYM-001, Phase III report; permit 85, 26 February 2018
The primary nasal-symptom comparison was nonsignificant (p=0.6708); selected secondary symptoms favored Thymodepressin.
Results and tables
Reported findings and study design
Open randomized active-comparator allergy study; 72 randomized (36/36); one comparator withdrawal. Thymodepressin nasal spray versus standard care.
Population or model 72 randomized, 36 per arm; one comparator withdrawal
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Primary nasal-symptom comparison | p=0.6708; no significant between-group difference. | Day 16 |
| Selected secondary symptoms and sleep | Some comparisons favored treatment; these do not overturn the neutral primary outcome. | |
| Drug-related adverse events | Reported in both groups; exact counts not extracted; comparison p=1. | |
| Later follow-up | Day 47±2, approximately 30 days after therapy. |
Superiority and noninferiority are not established. The report-date inconsistency and unsigned fields require a final-version check.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- 72 randomized, 36 per arm; one comparator withdrawal
- Source reviewed
- Original report text and companion HTML checked. Investigators: A. A. Odegova, A. A. Bagretsova, K. I. Lobanov, A. F. Pyankov and M. G. Omelyanenko.
Study limitations
- Open active-comparator design; nonsignificance does not establish noninferiority.
- Report dated 8 October 2018 precedes the listed 20 October study end; signed final version needs authentication.
- Allergy study, separate from rheumatoid-arthritis protocol ИБХ-ТД01.
Reviewed 2026-11-06.
Study involving people · 2002
[Use of thymodepressin for treating autoimmune cytopenia]
The report describes higher hemoglobin in autoimmune hemolytic anemia and higher platelet counts in immune thrombocytopenia, alongside reductions in lymphocyte activation measures.
Study notes and original source
[Use of thymodepressin for treating autoimmune cytopenia]
Vinogradova IuE, Zamulaeva IA, Pavlov VV, Selivanova EI, Deĭgin VI, Smirnova SG, Orlova NV, Saenko AS · Terapevticheskii arkhiv
The report describes higher hemoglobin in autoimmune hemolytic anemia and higher platelet counts in immune thrombocytopenia, alongside reductions in lymphocyte activation measures.
- Population / setting
- 22 patients with autoimmune cytopenias
- Source reviewed
- Original publication abstract checked; full methodological appraisal pending.
Study limitations
- Uncontrolled clinical report; changes cannot establish an independent treatment effect.
- The abstract supplies no reliable comparative effect size or comprehensive safety estimate.
Reviewed 2026-11-05.
Observational study · 2013
Current immunopathological therapy of psoriasis
The authors report a 90.4% PASI reduction by day 20 and three-year remission in 70%. The same article describes seven withdrawals following drug-related skin eruptions.
Study notes and original source
Current immunopathological therapy of psoriasis
E. A. Batkaev, I. A. Chistyakova · Effective Pharmacotherapy. 8/2013
The authors report a 90.4% PASI reduction by day 20 and three-year remission in 70%. The same article describes seven withdrawals following drug-related skin eruptions.
Results and tables
Reported findings and study design
Historical clinical report with 50 course completers and seven reported discontinuations.
Population or model 50 course completers described; seven withdrawals also reported
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| PASI change | Reported 90.4% reduction by day 20 | |
| Three-year remission | Reported in 70%; follow-up denominator and ascertainment need clarification | |
| Treatment withdrawals | Seven cases after skin eruptions; no adverse-event rate inferred |
Completer-only tolerability cannot represent everyone exposed. Historical comparisons and co-treatment prevent a reliable comparative efficacy estimate.
Source for these results ↗ · Reviewed 2026-11-05
- Population / setting
- 50 course completers described; seven withdrawals also reported
- Source reviewed
- Publisher-hosted Russian article, including efficacy paragraph and discontinuation statement, checked.
Study limitations
- Historical comparisons and combined care do not yield a randomized treatment effect.
- The relationship between the 50 completers and seven withdrawals is not fully reconciled; do not calculate an adverse-event rate.
- No adverse effects among completers does not mean no adverse effects among everyone treated.
Reviewed 2026-11-05.
Comparison in people · 2014
Evaluation of the efficacy and safety of a Russian selective immune suppressor in treating patients with psoriasis
The Russian text reports more than 75% PASI improvement by day 25 in 90% versus 41% in the moderate-disease comparison. Overall favorable outcomes were reported in 100% versus 82.9%.
Study notes and original source
Evaluation of the efficacy and safety of a Russian selective immune suppressor in treating patients with psoriasis
A. A. Kubylinskiy, N. G. Korotkiy, A. A. Tikhomirov, V. Yu. Udzhukhu, N. M. Sharova · Clinical Dermatology and Venereology. 2014;12(5):68–74
The Russian text reports more than 75% PASI improvement by day 25 in 90% versus 41% in the moderate-disease comparison. Overall favorable outcomes were reported in 100% versus 82.9%.
Results and tables
Reported findings and study design
140-patient clinical comparison; the quoted PASI response appears within the moderate-psoriasis discussion.
Population or model 140 patients with moderate or severe psoriasis
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| PASI reduction greater than 75% by day 25 | 90% with Thymodepressin versus 41% with conventional care |
The subgroup denominator is not verified; these percentages must not be described as responses among all 140 participants. Blinding, allocation and concurrent treatment limit attribution.
Source for these results ↗ · Reviewed 2026-11-05
- Population / setting
- 140 patients with moderate or severe psoriasis
- Source reviewed
- Publisher Russian full text checked. Issue year is 2014; the later website posting date is not a new study date.
Study limitations
- The paper gives these PASI percentages in its discussion of moderate psoriasis. The unclear denominator prevents estimating a response rate across all 140 patients.
- Blinding and allocation concealment are not established. Concurrent care and treatment selection limit causal attribution.
- The comparator reflects conventional care at publication, not contemporary targeted biologics.
Reviewed 2026-11-05.
Comparison in people · 2014
Combined therapy of patients with psoriasis
The publication compares combination treatment against Thymodepressin monotherapy and reports categorical skin responses.
Study notes and original source
Combined therapy of patients with psoriasis
O. V. Degtyarev, V. V. Dumchenko, T. A. Tkachenko, O. V. Zhizhimova, E. G. Bakhmutova, I. N. Selivanova, I. A. Erina · Russian Journal of Skin and Venereal Diseases. 2014
The publication compares combination treatment against Thymodepressin monotherapy and reports categorical skin responses.
- Population / setting
- 72 patients: 42 prednisolone plus Thymodepressin; 30 Thymodepressin alone
- Source reviewed
- Original publisher article and Russian/English summary checked.
Study limitations
- No group received neither treatment, so the independent effect of Thymodepressin cannot be estimated.
- Some response percentages in the English abstract do not match their stated counts; no pooled response estimate is reproduced.
Reviewed 2026-11-05.
Randomized study in people · 2017
Clinical evaluation of combined immunosuppressive therapy for psoriasis
This small study compares narrow-band UVB, Thymodepressin and their combination over 21 days, reporting a stronger response with combined care.
Study notes and original source
Clinical evaluation of combined immunosuppressive therapy for psoriasis
V. A. Okhlopkov, O. V. Pravdina, D. S. Melnichenko, E. I. Poleschuk, T. V. Repina · Clinical Dermatology and Venereology. 2017;16(3):64–69
This small study compares narrow-band UVB, Thymodepressin and their combination over 21 days, reporting a stronger response with combined care.
- Population / setting
- 48 patients allocated to three groups of 16; five pregnant patients followed separately
- Source reviewed
- Original publisher text checked for allocation, separate pregnancy cohort and short-term findings.
Study limitations
- Only 48 participants belong to the randomized comparison; the five pregnant patients are a separate nonrandomized cohort.
- Open-label comparison, small groups and short follow-up limit efficacy and safety conclusions.
Reviewed 2026-11-05.
Planned study · 2013
Thymodepressin plus methotrexate in rheumatoid arthritis — protocol ИБХ-ТД01
Registry reproduction describes a Phase IV randomized, multicenter, double-blind, placebo-controlled add-on trial with ACR20 as the primary assessment. Listed dates: 4 February 2013 to 30 September 2016.
Study notes and original source
Thymodepressin plus methotrexate in rheumatoid arthritis — protocol ИБХ-ТД01
· Third-party trial-registry reproduction
Pharma Bio — listed sponsor · Registration No. 77, 4 February 2013; protocol ИБХ-ТД01
Registry reproduction describes a Phase IV randomized, multicenter, double-blind, placebo-controlled add-on trial with ACR20 as the primary assessment. Listed dates: 4 February 2013 to 30 September 2016.
- Population / setting
- 142 planned participants; 14 listed sites; 12-week primary assessment
- Source reviewed
- Third-party registry reproduction checked; protocol evidence only.
Study limitations
- ClinLine reproduces a registry record; the original regulatory entry was not independently recovered.
- Planned enrollment is not confirmed enrollment or completion. No results or primary-endpoint success were verified.
- Historical listed dates do not establish current trial status.
Reviewed 2026-11-05.
Comparison in people · 2008
Idiopathic inflammatory myopathies — Alekseeva doctoral dissertation abstract
The author reports increased proximal arm and leg strength and lower IL-8 and TNF-α production; the IL-10 change was a nonsignificant trend.
Study notes and original source
Idiopathic inflammatory myopathies — Alekseeva doctoral dissertation abstract
Tatyana M. Alekseeva · Doctoral dissertation author abstract. St. Petersburg, 2008
The author reports increased proximal arm and leg strength and lower IL-8 and TNF-α production; the IL-10 change was a nonsignificant trend.
Results and tables
Reported findings and study design
15 adjunctively treated patients versus 15 symptomatic-care comparators, reported in an author-abstract transcription.
Population or model 30 patients: 15 adjunctive Thymodepressin; 15 symptomatic-care comparators
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Proximal arm strength | Reported increase | p<0.01 |
| Proximal leg strength | Reported increase | p<0.001 |
| IL-8 / TNF-α production | Reported reductions | p<0.01 / p<0.001 |
| IL-10 production | Nonsignificant upward trend | p=0.08 |
These are reported pre/post signals, not verified between-group effect estimates. Original full-thesis authentication, allocation and durable outcomes remain unresolved.
Source for these results ↗ · Reviewed 2026-11-05
- Population / setting
- 30 patients: 15 adjunctive Thymodepressin; 15 symptomatic-care comparators
- Source reviewed
- Author-abstract transcription checked for 15/15 comparison and reported endpoints; original thesis remains a recovery priority.
Study limitations
- Accessed through a third-party transcription of the author abstract, not an authenticated full dissertation PDF.
- Small comparison without established randomization or blinding.
- Reported p values are not effect sizes and do not establish durable disease control.
Reviewed 2026-11-05.
Animal research · 2021
Thymodepressin-Unforeseen Immunosuppressor
Experimental anti-fibrillarin autoantibody responses were lower in selected Thymodepressin groups, including comparisons begun after autoimmunity developed.
Study notes and original source
Thymodepressin-Unforeseen Immunosuppressor
Deigin VI, Vinogradova JE, Vinogradov DL, Krasilshchikova MS, Ivanov VT · Molecules (Basel, Switzerland)
Experimental anti-fibrillarin autoantibody responses were lower in selected Thymodepressin groups, including comparisons begun after autoimmunity developed.
- Population / setting
- Small mouse autoimmunity experiments, approximately five to eight animals per group
- Source reviewed
- Primary open-access paper checked for animal endpoints and group sizes; not a completed systematic appraisal.
Study limitations
- Small induced-animal model, not a human lupus trial.
- Comparisons against cyclosporine do not establish clinical superiority or equivalent human exposures.
- The article combines experimental results with historical clinical discussion; those evidence types must remain separate.
Reviewed 2026-11-05.
Review of earlier studies · 2024
The First Reciprocal Activities of Chiral Peptide Pharmaceuticals: Thymogen and Thymodepressin, as Examples
The review contrasts immune stimulation and suppression across peptide stereochemistry and discusses lymphocyte activation and marrow distribution.
Study notes and original source
The First Reciprocal Activities of Chiral Peptide Pharmaceuticals: Thymogen and Thymodepressin, as Examples
V. I. Deigin and colleagues · International Journal of Molecular Sciences. 25(9):5042
The review contrasts immune stimulation and suppression across peptide stereochemistry and discusses lymphocyte activation and marrow distribution.
- Population / setting
- Review of chiral peptide pharmacology
- Source reviewed
- Open-access review checked for identity distinctions and mechanistic context.
Study limitations
- Narrative synthesis is not independent clinical replication.
- Radiolabel tissue exposure is not proof of intact-peptide targeting or selective suppression of autoreactive cells.
Reviewed 2026-11-05.
Animal research · 2005
Effects of iEW synthetic peptide isomers on bone marrow colony-forming capacity in vivo.
Experiments with peptide isomers and neuraminidase linked differing colony-forming responses to the T-cell microenvironment. The authors proposed shared CD34-associated surface interactions.
Study notes and original source
Effects of iEW synthetic peptide isomers on bone marrow colony-forming capacity in vivo.
Related L- and D-iEW isomers; preparation equivalence is not inferred
Format: Journal article · Reviewed: Indexed abstract reviewed
O. V. Semina, T. N. Semenets, I. A. Zamulaeva, E. I. Selivanova, Ya. V. Malyutina, Yu. A. Semin, V. I. Deigin, A. S. Saenko · Bulletin of Experimental Biology and Medicine. 140(3):348–351
Experiments with peptide isomers and neuraminidase linked differing colony-forming responses to the T-cell microenvironment. The authors proposed shared CD34-associated surface interactions.
- Population / setting
- Mice; splenic colony-forming, CD34-positive-cell and T-cell assays
- Source reviewed
- Original publication metadata and indexed abstract checked; full methods and tables not appraised.
Study limitations
- Mechanistic interpretation does not establish CD34 as a directly bound receptor.
- Related-isomer experiments do not prove clinical effects of either marketed preparation.
- Colony formation is not proof of long-term self-renewing stem-cell expansion.
Reviewed 2026-10-03.
Animal research · 2020
Novel platform for the preparation of synthetic orally active peptidomimetics with hemoregulating activity. II. Hemosuppressor activity of 2,5-diketopiperazine-based cyclopeptides.
The later platform paper studies suppressive cyclic derivatives. Opposing experimental effects do not establish a shared receptor or clinical interchangeability.
Study notes and original source
Novel platform for the preparation of synthetic orally active peptidomimetics with hemoregulating activity. II. Hemosuppressor activity of 2,5-diketopiperazine-based cyclopeptides.
Preparation-specific research; no equivalence inferred
Deigin V, Ksenofontova O, Yatskin O, Goryacheva A, Ignatova A, Feofanov A, Ivanov V. · International immunopharmacology
The later platform paper studies suppressive cyclic derivatives. Opposing experimental effects do not establish a shared receptor or clinical interchangeability.
- Population / setting
- See original report; human, animal and laboratory components must be distinguished.
- Source reviewed
- Indexed metadata and abstract checked via Europe PMC. Original full methods not reviewed.
Study limitations
- The abstract leaves the preparation and study methods unclear.
- Related publications may share experiments; source count is not independent-study count.
Reviewed 2026-10-02.
Animal research · 2009
The effects of the EW--peptide optical and chemical isomers on the hemopoietic stem cells in intact and irradiated mice.
Follow-up record on optical and chemical isomers. No abstract was recovered; overlap with earlier experiments remains unresolved.
Study notes and original source
The effects of the EW--peptide optical and chemical isomers on the hemopoietic stem cells in intact and irradiated mice.
Preparation-specific research; no equivalence inferred
Deigin VI, Semenets TN, Zamulaeva IA, Maliutina YV, Selivanova EI, Saenko AS, Semina OV. · Advances in experimental medicine and biology
Follow-up record on optical and chemical isomers. No abstract was recovered; overlap with earlier experiments remains unresolved.
- Population / setting
- See original report; human, animal and laboratory components must be distinguished.
- Source reviewed
- Indexed metadata only checked via Europe PMC. Original full methods not reviewed. Study type is based on the database record and abstract, where available.
Study limitations
- Citation only. The preparation and methods are unverified.
- Related publications may share experiments; source count is not independent-study count.
Reviewed 2026-10-02.
Animal research · 2007
Thymodepressin inhibits migration of CD34+ cells from bone marrow in normal and granulocyte CSF-stimulated hemopoiesis.
Mouse CD34-positive cell distribution and adhesion-marker changes suggest altered trafficking. They do not identify a direct molecular receptor or demonstrate human stem-cell expansion.
Study notes and original source
Thymodepressin inhibits migration of CD34+ cells from bone marrow in normal and granulocyte CSF-stimulated hemopoiesis.
Preparation-specific research; no equivalence inferred
Semina OV, Semenets TN, Zamulaeva IA, Selivanova EI, Il'ina TP, Malyutina YV, Semin DY, Deigin VI, Saenko AS. · Bulletin of experimental biology and medicine
Mouse CD34-positive cell distribution and adhesion-marker changes suggest altered trafficking. They do not identify a direct molecular receptor or demonstrate human stem-cell expansion.
- Population / setting
- See original report; human, animal and laboratory components must be distinguished.
- Source reviewed
- Indexed metadata and abstract checked via Europe PMC. Original full methods not reviewed.
Study limitations
- The abstract leaves the preparation and study methods unclear.
- Related publications may share experiments; source count is not independent-study count.
Reviewed 2026-10-02.
Animal research · 2007
The effects of the EW dipeptide optical and chemical isomers on the CFU-S population in intact and irradiated mice.
Optical configuration, peptide linkage and administration before or after irradiation affected colony-forming responses. Normal marrow and injury recovery are different endpoints.
Study notes and original source
The effects of the EW dipeptide optical and chemical isomers on the CFU-S population in intact and irradiated mice.
Preparation-specific research; no equivalence inferred
Deigin VI, Semenets TN, Zamulaeva IA, Maliutina YV, Selivanova EI, Saenko AS, Semina OV. · International immunopharmacology
Optical configuration, peptide linkage and administration before or after irradiation affected colony-forming responses. Normal marrow and injury recovery are different endpoints.
- Population / setting
- See original report; human, animal and laboratory components must be distinguished.
- Source reviewed
- Indexed metadata and abstract checked via Europe PMC. Original full methods not reviewed.
Study limitations
- The abstract leaves the preparation and study methods unclear.
- Related publications may share experiments; source count is not independent-study count.
Reviewed 2026-10-02.
Animal research · 2006
Effects of structural and "mixed" isomers of Glu-Trp dipeptide on normal hemopoietic stem cells.
Glu–Trp isomers produced different colony-assay effects depending on stereochemistry and bond position. Results cannot be reduced to a universal L-stimulates/D-suppresses rule.
Study notes and original source
Effects of structural and "mixed" isomers of Glu-Trp dipeptide on normal hemopoietic stem cells.
Preparation-specific research; no equivalence inferred
Semina OV, Semenets TN, Zamulaeva IA, Selivanova EI, Malyutina YV, Saenko AS, Deigin VI. · Bulletin of experimental biology and medicine
Glu–Trp isomers produced different colony-assay effects depending on stereochemistry and bond position. Results cannot be reduced to a universal L-stimulates/D-suppresses rule.
- Population / setting
- See original report; human, animal and laboratory components must be distinguished.
- Source reviewed
- Indexed metadata and abstract checked via Europe PMC. Original full methods not reviewed.
Study limitations
- The abstract leaves the preparation and study methods unclear.
- Related publications may share experiments; source count is not independent-study count.
Reviewed 2026-10-02.
Animal research · 2005
[Thymodepressin protects murine bone marrow CFU-S from the hyperthermic damage].
Experiments found differing heat responses in normal marrow precursors and tumor model cells. Heating cells to 43°C does not demonstrate whole-body heat tolerance or occupational protection.
Study notes and original source
[Thymodepressin protects murine bone marrow CFU-S from the hyperthermic damage].
Preparation-specific research; no equivalence inferred
Semenets TN, Semina OV, Deĭgin VI, Maliutina IaV, Saenko AS. · Radiatsionnaia biologiia, radioecologiia
Experiments found differing heat responses in normal marrow precursors and tumor model cells. Heating cells to 43°C does not demonstrate whole-body heat tolerance or occupational protection.
- Population / setting
- See original report; human, animal and laboratory components must be distinguished.
- Source reviewed
- Indexed metadata and abstract checked via Europe PMC. Original full methods not reviewed.
Study limitations
- The abstract leaves the preparation and study methods unclear.
- Related publications may share experiments; source count is not independent-study count.
Reviewed 2026-10-02.
Animal research · 2001
Synthetic peptide thymodepressin promoted take of transplanted hemopoietic precursor cells in the bone marrow of irradiated mice.
A mouse transplantation experiment measured donor-cell colony formation following pretreatment and irradiation. The proposed marrow-microenvironment mechanism remains a hypothesis.
Study notes and original source
Synthetic peptide thymodepressin promoted take of transplanted hemopoietic precursor cells in the bone marrow of irradiated mice.
Preparation-specific research; no equivalence inferred
Semina OV, Semenets TN, Poverennyi AM, Deigin VI. · Bulletin of experimental biology and medicine
A mouse transplantation experiment measured donor-cell colony formation following pretreatment and irradiation. The proposed marrow-microenvironment mechanism remains a hypothesis.
Results and tables
Reported findings and study design
Animal marrow-transplant experiment; Thymodepressin at 48, 24 and 2 hours before irradiation/transplantation.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Day-9 splenic colonies after allogeneic transplant | Fivefold increase versus control | |
| Colony assessment | Days 9 and 12 |
Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- See original report; human, animal and laboratory components must be distinguished.
- Source reviewed
- Indexed metadata and abstract checked via Europe PMC. Original full methods not reviewed.
Study limitations
- The abstract leaves the preparation and study methods unclear.
- Related publications may share experiments; source count is not independent-study count.
Reviewed 2026-10-02.
Animal research · 2000
[The synthetic peptide D-(iEW) (thymodepressin) protects bone marrow CFU-S from ionizing radiation exposure].
Pre-irradiation treatment reduced the cycling fraction of marrow colony-forming cells and was associated with later colony recovery. Timing and model are essential to interpretation.
Study notes and original source
[The synthetic peptide D-(iEW) (thymodepressin) protects bone marrow CFU-S from ionizing radiation exposure].
Preparation-specific research; no equivalence inferred
Semina OV, Deĭgin VI, Semenets TN, Beziaev GP, Poverennyĭ AM. · Radiatsionnaia biologiia, radioecologiia
Pre-irradiation treatment reduced the cycling fraction of marrow colony-forming cells and was associated with later colony recovery. Timing and model are essential to interpretation.
Results and tables
Reported findings and study design
Animal marrow-radiation experiment; Thymodepressin two days before 4 Gy irradiation.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Marrow CFU-S recovery | Three- to fivefold the irradiated-control value |
A hematopoietic colony endpoint, not a general human radiation-protection estimate.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- See original report; human, animal and laboratory components must be distinguished.
- Source reviewed
- Indexed metadata and abstract checked via Europe PMC. Original full methods not reviewed.
Study limitations
- The abstract leaves the preparation and study methods unclear.
- Related publications may share experiments; source count is not independent-study count.
Reviewed 2026-10-02.
Review of earlier studies · 2023
Advancement from Small Peptide Pharmaceuticals to Orally Active Piperazine-2,5-dion-Based Cyclopeptides
Development-group review connecting small peptides with cyclic peptidomimetics, including AWE18. AWE18 and CP-88 are separate candidates. Review descriptions of oral activity are not independent clinical trials.
Study notes and original source
Advancement from Small Peptide Pharmaceuticals to Orally Active Piperazine-2,5-dion-Based Cyclopeptides
Defined synthetic peptide / analogue
Vladislav Deigin, Natalia Linkova, Olga Volpina · International Journal of Molecular Sciences 24(17):13534
Development-group review connecting small peptides with cyclic peptidomimetics, including AWE18. AWE18 and CP-88 are separate candidates. Review descriptions of oral activity are not independent clinical trials.
- Population / setting
- Source-specific experimental population
- Source reviewed
- Review full text retrieved via Europe PMC. Primary compound-specific studies require separate appraisal.
Study limitations
- Independent replication and full risk-of-bias appraisal remain unresolved.
- No personalized treatment or safety conclusion follows from this record.
Reviewed 2026-10-02.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗